{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:06:48Z","timestamp":1754154408303,"version":"3.41.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"DOI":"10.7759\/cureus.88649","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T09:12:01Z","timestamp":1753348321000},"source":"Crossref","is-referenced-by-count":0,"title":["Oxymetazoline and Blepharoptosis: A Case Series and Proposed Treatment Algorithm"],"prefix":"10.7759","author":[{"given":"Emanuella M","family":"Brito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titilopemi","family":"Odulanmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A","family":"Vera Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Foran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin I","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres G","family":"Sarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14361","article-title":"Botulinum toxin-induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options","volume":"20","author":"Nestor MS","year":"2021","unstructured":"Nestor MS, Han H, Gade A, Fischer D, Saban Y, Polselli R. Botulinum toxin-induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options. J Cosmet Dermatol. 2021, 20:3133-46. 10.1111\/jocd.14361","journal-title":"J Cosmet Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20517\/2347-9264.2020.110","article-title":"More than meets the eye: A comprehensive review of blepharoptosis","volume":"8","author":"Floyd MT","year":"2021","unstructured":"Floyd MT, Kim HJ. More than meets the eye: A comprehensive review of blepharoptosis. Plast Aesthet Res. 2021, 8:1. 10.20517\/2347-9264.2020.110","journal-title":"Plast Aesthet Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01547-5","article-title":"A review of acquired blepharoptosis: Prevalence, diagnosis, and current treatment options","volume":"35","author":"Bacharach J","year":"2021","unstructured":"Bacharach J, Lee WW, Harrison AR, Freddo TF. A review of acquired blepharoptosis: Prevalence, diagnosis, and current treatment options. Eye. 2021, 35:2468-81. 10.1038\/s41433-021-01547-5","journal-title":"Eye"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab400","article-title":"Changes to eye whiteness and eyelid\/brow position with topical oxymetazoline in aesthetic patients","volume":"42","author":"Ugradar S","year":"2022","unstructured":"Ugradar S, Kim JS, Trost N, et al.. Changes to eye whiteness and eyelid\/brow position with topical oxymetazoline in aesthetic patients. Aesthet Surg J. 2022, 42:582-9. 10.1093\/asj\/sjab400","journal-title":"Aesthet Surg J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.10.026","article-title":"Incidence and demographics of childhood ptosis","volume":"118","author":"Griepentrog GJ","year":"2011","unstructured":"Griepentrog GJ, Diehl NN, Mohney BG. Incidence and demographics of childhood ptosis. Ophthalmology. 2011, 118:1180-3. 10.1016\/j.ophtha.2010.10.026","journal-title":"Ophthalmology"},{"key":"ref6","article-title":"Ptosis","author":"Shahzad B","year":"2025","unstructured":"Shahzad B, Siccardi MA. Ptosis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2007.0116","article-title":"Passive and oxymetazoline-enhanced delivery with a lens device: Pharmacokinetics and efficacy studies with rabbits","volume":"24","author":"Miller DJ","year":"2008","unstructured":"Miller DJ, Li SK, Tuitupou AL, et al.. Passive and oxymetazoline-enhanced delivery with a lens device: Pharmacokinetics and efficacy studies with rabbits. J Ocul Pharmacol Ther. 2008, 24:385-91. 10.1089\/jop.2007.0116","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2023.02.006","article-title":"The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial","volume":"80","author":"Shoji MK","year":"2023","unstructured":"Shoji MK, Markatia Z, Ameli K, Bayaraa M, Clauss KD, Ugradar S, Lee WW. The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial. J Plast Reconstr Aesthet Surg. 2023, 80:66-74. 10.1016\/j.bjps.2023.02.006","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.3812","article-title":"Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: A pooled analysis of 2 randomized clinical trials","volume":"138","author":"Slonim CB","year":"2020","unstructured":"Slonim CB, Foster S, Jaros M, Kannarr SR, Korenfeld MS, Smyth-Medina R, Wirta DL. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: A pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020, 138:1168-75. 10.1001\/jamaophthalmol.2020.3812","journal-title":"JAMA Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001800","article-title":"Case report: Treatment of myasthenic ptosis with topical ocular oxymetazoline","volume":"98","author":"Cooper J","year":"2021","unstructured":"Cooper J, Yang D. Case report: Treatment of myasthenic ptosis with topical ocular oxymetazoline. Optom Vis Sci. 2021, 98:1317-20. 10.1097\/OPX.0000000000001800","journal-title":"Optom Vis Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S306155","article-title":"Rapid and sustained eyelid elevation in acquired blepharoptosis with oxymetazoline 0.1%: Randomized phase 3 trial results","volume":"15","author":"Bacharach J","year":"2021","unstructured":"Bacharach J, Wirta DL, Smyth-Medina R, et al.. Rapid and sustained eyelid elevation in acquired blepharoptosis with oxymetazoline 0.1%: Randomized phase 3 trial results. Clin Ophthalmol. 2021, 15:2743-51. 10.2147\/OPTH.S306155","journal-title":"Clin Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S322326","article-title":"Safety of once-daily oxymetazoline HCl ophthalmic solution, 0.1% in patients with acquired blepharoptosis: Results from four randomized, double-masked clinical trials","volume":"15","author":"Wirta DL","year":"2021","unstructured":"Wirta DL, Korenfeld MS, Foster S, et al.. Safety of once-daily oxymetazoline HCl ophthalmic solution, 0.1% in patients with acquired blepharoptosis: Results from four randomized, double-masked clinical trials. Clin Ophthalmol. 2021, 15:4035-48. 10.2147\/OPTH.S322326","journal-title":"Clin Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad070","article-title":"Management of severe botulinum-induced eyelid ptosis with pretarsal botulinum toxin and oxymetazoline hydrochloride 0.1","volume":"43","author":"Bernardini FP","year":"2023","unstructured":"Bernardini FP, Skippen B, Croasdell B, et al.. Management of severe botulinum-induced eyelid ptosis with pretarsal botulinum toxin and oxymetazoline hydrochloride 0.1. Aesthet Surg J. 2023, 43:955-61. 10.1093\/asj\/sjad070","journal-title":"Aesthet Surg J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03493-6","article-title":"Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: A case series","volume":"16","author":"Sung J","year":"2022","unstructured":"Sung J, Song A, Song M, Song J. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: A case series. J Med Case Rep. 2022, 16:299. 10.1186\/s13256-022-03493-6","journal-title":"J Med Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1997.13.363","article-title":"Efficacy of oxymetazoline eye drops in non-infectious conjunctivitis, the most common cause of acute red eyes","volume":"13","author":"Xuan B","year":"1997","unstructured":"Xuan B, Chiou GC. Efficacy of oxymetazoline eye drops in non-infectious conjunctivitis, the most common cause of acute red eyes. J Ocul Pharmacol Ther. 1997, 13:363-7. 10.1089\/jop.1997.13.363","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/351063-oxymetazoline-and-blepharoptosis-a-case-series-and-proposed-treatment-algorithm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T09:12:02Z","timestamp":1753348322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/351063-oxymetazoline-and-blepharoptosis-a-case-series-and-proposed-treatment-algorithm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.88649","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}